Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;26(1):51-60.
doi: 10.1038/eye.2011.302. Epub 2011 Dec 16.

Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration

K Takeuchi  1 , S Kachi, E Iwata, K Ishikawa, H Terasaki
Affiliations

Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration

K Takeuchi et al. Eye (Lond). 2012 Jan.

Abstract

Purpose: To evaluate the changes in the best-corrected visual acuity (BCVA) after 1 year and after ≥ 5 years after macular translocation for age-related macular degeneration (AMD) or myopic choroidal neovascularisation (mCNV).

Methods: The medical records of 61 consecutive patients who underwent macular translocation with 360° retinotomy for AMD (35 eyes) or mCNV (26 eyes) were reviewed. Overall, 40 patients, 17 mCNV and 23 AMD, were followed for at least 5 years. BCVA and area of the Goldmann visual field (VF) measured before, 12 months after surgery, and at the final visit.

Results: In the 23 AMD eyes followed for ≥ 5 years, the mean preoperative BCVA was 1.149 ± 0.105 logMAR units, which significantly improved to 0.69 ± 0.06 logMAR units at 1 year (P<0.001). This BCVA was maintained at 0.633 ± 0.083 logMAR units on their final examination. In the 17 eyes with mCNV followed for ≥ 5 years, the mean preoperative BCVA was 1.083 ± 0.119 logMAR units, which was significantly improved to 0.689 ± 0.121 logMAR units at 1 year (P = 0.001). This BCVA was maintained at 0.678 ± 0.142 logMAR units on their final examination. The area of the VF was significantly decreased at 12 months and did not change significantly thereafter.

Conclusions: Our results show that macular translocation surgery significantly improves the BCVA and significantly decreases the VF area of eyes with mCNV or AMD after first 1 year. The BCVA and VF area do not change significantly from the values at 1 year for at least 5 years.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of macular translocation surgery on the BCVA in the AMD eyes. Overall, 23 eyes were followed for ≥5 years (filled circle) and 12 eyes were followed for <5 years (open circle). Scatter plots of the BCVA before and 12 months after surgery (a) and at the final examination (b) are shown. The BCVA is plotted in logMAR units. The mean BCVA of the 35 eyes examined (open circle) and that of the 23 eyes followed for ≥5 years months (filled circle) are shown (c). The BCVA improved significantly at 12 months and did not decrease significantly thereafter. The error bars represent the SEMs. *P=0.01, **P<0.001 by Wilcoxon's signed-rank test.
Figure 2
Figure 2
Effect of macular translocation surgery on the BCVA in myopic eyes with a CNV. Overall, 17 eyes were followed for ≥5 years (filled circle) and 9 eyes were followed for <60 months (open circle). Scatter plots of the BCVA before and 12 months after surgery (a) and at the final examination (b) are shown. The BCVAs are plotted in logMAR units. The mean BCVA of the 26 eyes (open circle) and that of 17 eyes followed for ≥5 years (filled circle) are shown (c). The BCVA significantly improved at 12 months and was stable thereafter. The error bars represent the SEMs. *P=0.001, **P<0.001 by Wilcoxon's signed-rank test.
Figure 3
Figure 3
Changes in the area of the VF in mCNV (grey) and AMD (black) eyes are shown. The VF decreased after the surgery but no significant change was observed after 12 months. The error bars represent the SEMs. *P<0.001 by Wilcoxon's signed-rank test.
See this image and copyright information in PMC

References

    1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933–943. - PubMed
    1. Chan WM, Ohji M, Lai TY, Liu DT, Tano Y, Lam DS. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol. 2005;89:1522–1528. - PMC - PubMed
    1. Du H, Lim SL, Grob S, Zhang K. Induced pluripotent stem cell therapies for geographic atrophy of age-related macular degeneration. Semin Ophthalmol. 2011;26:216–224. - PMC - PubMed
    1. Falkner-Radler CI, Krebs I, Glittenberg C, Povazay B, Drexler W, Graf A, et al. Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study. Br J Ophthalmol. 2011;95 (3:370–375. - PubMed
    1. Machemer R, Steinhorst UH. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1993;231:635–641. - PubMed

MeSH terms